Last reviewed · How we verify

Retin-A Micro 0.04% facial acne treatment

Bausch Health Americas, Inc. · Phase 2 active Small molecule

Retin-A Micro 0.04% facial acne treatment is a Small molecule drug developed by Bausch Health Americas, Inc.. It is currently in Phase 2 development. Also known as: facial acne treatment.

At a glance

Generic nameRetin-A Micro 0.04% facial acne treatment
Also known asfacial acne treatment
SponsorBausch Health Americas, Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Retin-A Micro 0.04% facial acne treatment

What is Retin-A Micro 0.04% facial acne treatment?

Retin-A Micro 0.04% facial acne treatment is a Small molecule drug developed by Bausch Health Americas, Inc..

Who makes Retin-A Micro 0.04% facial acne treatment?

Retin-A Micro 0.04% facial acne treatment is developed by Bausch Health Americas, Inc. (see full Bausch Health Americas, Inc. pipeline at /company/bausch-health-americas-inc).

Is Retin-A Micro 0.04% facial acne treatment also known as anything else?

Retin-A Micro 0.04% facial acne treatment is also known as facial acne treatment.

What development phase is Retin-A Micro 0.04% facial acne treatment in?

Retin-A Micro 0.04% facial acne treatment is in Phase 2.

Related